Cytokinetics Stock Forecast
NASDAQ: CYTKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 12:21 PM ET
CYTK analyst consensus
Consensus (22 analysts)
strong_buy
Avg. price target
$109.90+83.17%
- Strong buy 7
- Buy 13
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 22 Wall Street analysts covering Cytokinetics (2026-10-07), 20 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $109.90, with a high estimate of $146.00 and a low estimate of $85.00. The average target implies upside of 83.2% from the current price of $60.00.
The spread between the highest and lowest targets is 71.8%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CYTK.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 7 | 32% |
| Buy | 13 | 59% |
| Hold | 2 | 9% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $85.00 | +41.67% |
| Average target | $109.90 | +83.17% |
| High target | $146.00 | +143.33% |